Align Technology
ALGN
$190.07
+2.73%
Align Technology Inc. is a leading healthcare company that designs, manufactures, and markets the Invisalign system of clear aligners and the iTero family of intraoral scanners, operating within the medical devices industry. The company is the dominant market leader in clear aligners, controlling over 90% of the market, and has established a powerful competitive moat through its extensive network of over 230,000 trained dental professionals and its integrated digital platform linking scanners to treatment planning. The current investor narrative is heavily influenced by activist investor involvement, with Elliott Management taking a significant stake, which is seen as a catalyst to unlock value and improve operational execution, against a backdrop of debate over the stock's valuation and its growth trajectory in a post-pandemic normalization phase.…
ALGN
Align Technology
$190.07
Related headlines
ALGN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Align Technology's 12-month outlook, with a consensus price target around $247.09 and implied upside of +30.0% versus the current price.
Average Target
$247.09
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$152 - $247
Analyst target range
Analyst coverage data is limited in the provided set, with only 4 analysts shown providing estimates for revenue and EPS, but no explicit consensus price target or recommendation breakdown is available. The estimated EPS average for the period is $15.71, with a range from $15.52 to $16.15, indicating tight clustering and high conviction on near-term earnings. The estimated revenue average is $4.90 billion, with a similarly narrow range from $4.85 billion to $5.00 billion. Given the minimal explicit target data, the institutional ratings provide clearer sentiment: recent actions include an upgrade from HSBC (Hold to Buy) and Barclays (Equal Weight to Overweight), signaling a recent positive shift in analyst outlook. The prevailing actions among the firms listed are predominantly bullish, with ratings like Overweight, Outperform, and Buy from Wells Fargo, Piper Sandler, Stifel, Evercore ISI, and Mizuho, while Morgan Stanley and UBS maintain Neutral/Equal Weight stances. This pattern suggests the analyst community leans bullish, with the activist catalyst from Elliott Management likely reinforcing positive revisions, though the absence of a quantified average target price limits the precision of implied upside calculations.
Bulls vs Bears: ALGN Investment Factors
The bull and bear cases for ALGN are sharply defined, with the bullish side currently holding stronger evidence due to the powerful activist catalyst, dominant market position, and attractive forward valuation. The bear case is grounded in the reality of decelerating growth and a still-premium trailing multiple. The single most important tension in the investment debate is whether activist involvement and operational improvements can re-accelerate growth sufficiently to justify and sustain the stock's valuation premium, or if the company's maturation into a slower-growth phase will lead to permanent multiple compression. The resolution of this growth-versus-valuation dynamic will determine the stock's path over the next 12 months.
Bullish
- Activist Catalyst from Elliott Management: The recent large stake by Elliott Management provides a powerful catalyst to unlock shareholder value and improve operational execution. This has already driven a positive shift in analyst sentiment, with upgrades from HSBC and Barclays, and is a key driver behind the stock's 45.7% surge over the past six months.
- Dominant Market Position with High Moat: Align controls over 90% of the clear aligner market, supported by a network of over 230,000 trained dental professionals. This entrenched position, combined with an integrated digital platform, creates a significant competitive moat that is difficult to replicate, ensuring sustained pricing power and market leadership.
- Strong Cash Flow & Robust Balance Sheet: The company generates robust free cash flow of $593.2 million (TTM) and maintains a fortress balance sheet with a minimal debt-to-equity ratio of 0.028. This financial strength provides ample flexibility for strategic initiatives, share repurchases, and navigating economic cycles without liquidity concerns.
- Attractive Forward Valuation: The stock trades at a forward P/E of 15.4x, a significant discount to its trailing P/E of 27.6x, implying the market expects a substantial earnings recovery. This forward multiple is now more in line with sector peers, reducing valuation risk if growth stabilizes.
Bearish
- Growth Deceleration to Single Digits: Revenue growth has slowed markedly, with Q4 2025 YoY growth at just 5.26%, down from prior double-digit rates. This signals a transition from hyper-growth to a more mature phase, raising questions about the sustainability of its historical valuation premium.
- Premium Trailing Valuation vs. Peers: Despite the slowdown, the stock's trailing P/E of 27.6x remains elevated compared to many medical device peers trading in the low-20s. This premium is vulnerable to compression if growth fails to re-accelerate, posing a key risk to the share price.
- Quarterly Margin Volatility: Gross margin showed pressure in Q4 2025, dipping to 65.69% from a trailing average of 68.33%. While operating margin remained stable at 15.23%, this gross margin fluctuation indicates potential cost or pricing challenges that could impact profitability.
- High Beta & Volatility Risk: With a beta of 1.81, ALGN is 81% more volatile than the broader market. This amplifies downside risk during market corrections, as evidenced by its 52-week low of $122, representing a potential -36% downside from the current price of $190.07.
ALGN Technical Analysis
The stock is in a sustained uptrend, evidenced by a 1-year price change of +10.89% and a more pronounced 6-month surge of +45.70%. As of the latest close at $190.07, the price is trading at approximately 79% of its 52-week range ($122.00 to $208.31), positioning it closer to recent highs, which reflects strong momentum but also suggests the stock is not in deeply oversold territory. Recent momentum has been exceptionally strong, with the stock up 10.24% over the past month and 10.83% over the past three months, significantly outpacing the S&P 500's returns of 7.36% and 2.67% over the same periods, indicating accelerating bullish momentum. The stock's beta of 1.81 confirms it is approximately 81% more volatile than the broader market, which amplifies both gains and losses and is a critical consideration for risk management. Key technical levels are clearly defined, with immediate support at the 52-week low of $122.00 and major resistance at the 52-week high of $208.31. A decisive breakout above the $208 resistance would signal a resumption of the long-term bull trend and potentially target new highs, while a breakdown below the recent consolidation range near $166 would suggest a deeper correction. The stock's high beta of 1.81, coupled with a short ratio of 3.34, indicates it is a high-volatility name prone to sharp swings and susceptible to short squeezes, which investors must account for in position sizing.
Beta
1.81
1.81x market volatility
Max Drawdown
-39.7%
Largest decline past year
52-Week Range
$122-$208
Price range past year
Annual Return
+10.9%
Cumulative gain past year
| Period | ALGN Return | S&P 500 |
|---|---|---|
| 1m | +10.2% | +9.5% |
| 3m | +10.8% | +2.7% |
| 6m | +45.7% | +5.8% |
| 1y | +10.9% | +34.9% |
| ytd | +21.8% | +4.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALGN Fundamental Analysis
Revenue growth has been positive but is showing signs of deceleration; the most recent Q4 2025 revenue was $1.05 billion, representing a year-over-year growth of 5.26%, which is a slowdown from the stronger double-digit growth rates seen in prior years. Segment data reveals the Clear Aligner business, at $794.3 million, remains the dominant driver, comprising roughly 76% of total revenue, while Scanners and Services contributed $200.9 million, indicating the core aligner franchise is the primary growth engine. The growth trend implies a company transitioning from hyper-growth to a more mature, albeit still positive, growth phase, which is a focal point for investor debate. The company is profitable, with Q4 2025 net income of $135.8 million and a trailing twelve-month net margin of 10.17%. Profitability has shown quarterly volatility, with gross margin for Q4 2025 at 65.69%, down from the company's typical gross margin in the high-60% range as indicated by the trailing gross margin of 68.33%, suggesting some potential margin pressure. The operating margin for the quarter was 15.23%, which aligns closely with the trailing operating margin of 15.27%, indicating core operational profitability has remained stable despite the gross margin fluctuation. The balance sheet is exceptionally strong with minimal financial risk, featuring a very low debt-to-equity ratio of 0.028 and a healthy current ratio of 1.36. The company generates robust cash flow, with trailing twelve-month free cash flow of $593.2 million, providing ample internal funding for growth initiatives and share repurchases. Return on equity (ROE) stands at 10.13%, which, while positive, is not exceptionally high, suggesting there may be room for improved capital efficiency, a potential area of focus for activist investors.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$593223000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALGN Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 27.6x and a forward P/E of 15.4x based on estimated EPS. The significant gap between trailing and forward multiples implies the market expects a substantial recovery in earnings growth over the next twelve months, pricing in improved profitability. Compared to sector averages, Align's valuation presents a mixed picture. Its trailing P/E of 27.6x is elevated relative to many medical device peers, often trading in the low-20s, suggesting a premium. This premium has historically been justified by its market dominance and superior growth profile, but as growth normalizes, the sustainability of this premium is under scrutiny. The Price-to-Sales (P/S) ratio of 2.81x and EV/Sales of 3.03x provide additional context for its market value relative to revenue. Historically, the current trailing P/E of 27.6x sits well below its peak multiples seen during the high-growth phases of 2021-2022, when P/E ratios frequently exceeded 50x and even 70x. This indicates the market has already de-rated the stock significantly from its pandemic-era highs. However, compared to its own longer-term history, the current multiple is not at a deep discount, suggesting the stock is fairly valued relative to its own historical norms, balancing matured growth against its entrenched competitive position.
PE
27.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~98x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not leverage or liquidity—the balance sheet is pristine—but rather the deceleration of top-line growth to 5.26% YoY, which pressures a valuation still carrying a premium trailing P/E of 27.6x. Furthermore, gross margin volatility, as seen in the Q4 dip to 65.69%, indicates potential vulnerability in the company's pricing power or cost structure. Revenue concentration is a significant operational risk, with the Clear Aligner segment comprising 76% of total sales, making the company highly dependent on a single product category's continued success.
Market & Competitive Risks: The stock faces substantial valuation compression risk. Its trailing P/E of 27.6x is above the sector median, and if growth remains in the mid-single digits, a de-rating toward peer multiples is likely. The high beta of 1.81 means the stock is highly sensitive to broader market swings, and its recent outperformance makes it susceptible to profit-taking and sector rotation. While its competitive moat is strong, the risk of disruptive new technologies or increased competition in the clear aligner space, though low probability, is a perpetual threat to its dominant market share.
Worst-Case Scenario: The worst-case scenario involves a combination of failed activist initiatives, a further deceleration of revenue growth below 5%, and a broader market sell-off that hits high-beta names hardest. This could trigger a severe de-rating, sending the stock back to test its 52-week low of $122. From the current price of $190.07, this represents a realistic downside of approximately -36%. A drawdown of this magnitude is plausible given the stock's historical max drawdown of -39.73% and its high volatility, especially if quarterly earnings disappoint and analyst sentiment turns negative.
